Bristol ‘take-under’ of Mirati is not so great for biotech

Bristol is paying $4.8 billion in cash to acquire Mirati. It's a small bolt-on acquisition for the company, which isn't overpaying.

October 10, 2023 Check out STAT+

Sponsored By

Molly Ferguson/STAT STAT+ | Bristol 'take-under' of Mirati is not so great for biotech, but company's new cancer target has potential Despite the underwhelming deal, PRMT5, the genetic cancer target that Mirati has been pursuing, seems to have potential. By Adam Feuerstein STAT+ | Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies Delfi appears to be the first in the growing field to focus its blood diagnostic test on lung cancer, the leading cause of cancer death. By Matthew Herper STAT+ | A Q&A with the global head of Boehringer Ingelheim's innovation unit At an event in London last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.  By Andrew Joseph Courtesy Olivia Newton-John Cancer Research institute STAT+ | Long underappreciated, gamma-delta T cells may be key to colon cancer defense, study says Cancer patients who had more gamma-delta T cells in their their gut tended to have better survival rates. That got researchers thinking. By Angus Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser